Germany’s SHI reform bill removes some of the most significant AMNOG restrictions introduced in 2022, including the price guardrails and combination therapy rebate. At the same time, it introduces new mechanisms that could increase pressure elsewhere through manufacturer rebates, price-volume controls and greater contracting activity.
In this on-demand webinar, Remap’s Anja Pownell and Nicole Lodowski examine what these reforms could mean in practice and where manufacturers should focus their attention. The discussion explores the commercial risks arising from an increasingly complex pharmaceutical pricing environment and the potential implications for pricing, forecasting, launch planning and wider market access strategy.
Access the Recording
What the session covers
- The key changes introduced by the SHI reform bill
- Where the greatest commercial risks may arise
- Considerations for pricing, forecasting and launch strategy
- Potential implications for international reference pricing and wider global market access